The Long-Term Management of Schizophrenia

Long-term management of schizophrenia combines continuous antipsychotic treatment with structured psychosocial interventions, physical health care, and relapse-prevention planning over many years.  The strategy is individualized, evolving with illness stage, treatment response, and patient preferences. 
 
Core pharmacological strategy
Maintenance antipsychotics: Continuing antipsychotic medication after remission markedly reduces relapse versus discontinuation/placebo, and all major guidelines recommend ongoing maintenance, usually for years and often indefinitely in recurrent illness. 
 
Dose and formulation: Use the minimum effective dose; long‑acting injectables are valuable where adherence is problematic or relapse risk is high. 
 
Treatment‑resistant illness: Clozapine should be introduced promptly after two adequate antipsychotic trials fail, with ongoing monitoring for metabolic, haematological, and cardiovascular adverse effects. 
 
Psychosocial and psychological treatments
Family work: Family interventions, especially structured psychoeducation, significantly reduce relapse and rehospitalization and are among the most effective long‑term psychosocial strategies. 
 
Individual therapies: Cognitive‑behavioural therapy for psychosis, social‑skills training, and cognitive remediation target persistent positive symptoms, social functioning, and cognitive impairment, improving long‑term functional outcomes beyond what medication alone achieves.
 
Relapse prevention and monitoring
Early‑warning plans: Patients and families are taught to recognize prodromal signs (sleep disruption, rising suspiciousness, subtle thought disorder) and have pre‑agreed steps for rapid review and dose adjustment. 
 
Routine outcome monitoring: Regular, structured assessment of symptoms, functioning, side effects, adherence, substance use, and quality of life helps identify non‑response or emerging deterioration so treatment can be adjusted promptly. 
 
Physical health and side‑effect management
Metabolic and cardiovascular risk: From the start, guidelines emphasize systematic monitoring of weight, waist circumference, blood pressure, lipids, and glucose, with active management of obesity, diabetes, and dyslipidaemia. 
 
Minimizing burden: Choice and adjustment of antipsychotics should explicitly balance efficacy against extrapyramidal symptoms, sedation, hyperprolactinaemia, and metabolic effects, as these both harm health and drive non‑adherence. 
 
Recovery, functioning, and duration of treatment
Functional rehabilitation: Supported employment/education, skills training, and community rehabilitation services are central for role recovery, housing stability, and social integration. 
 
Duration/possible reduction: Many clinicians opt for long‑term or indefinite pharmacological maintenance at the lowest effective dose, with any attempt at reduction or discontinuation done very gradually, with intensive monitoring, and generally reserved for carefully selected, stable individuals.
 
Guidelines for Antipsychotic Maintenance durations for Adults
For adults with schizophrenia-spectrum psychosis, most guidelines recommend at least 1–2 years of continuous antipsychotic maintenance after remission, often extending to 3–5 years or longer depending on relapse history and risk.  Beyond the first few years, many experts lean toward long‑term or indefinite low‑dose maintenance in multi‑episode or high‑risk patients, with any taper only in carefully selected, closely monitored cases. 

​First‑episode psychosis
WHO mhGAP and related guidance: continue antipsychotic treatment for a minimum of 7–12 months after full and sustained remission from a first psychotic episode. 
 
Other national guidelines: recommend at least 12–18 months of maintenance after positive‑symptom remission in first‑episode schizophrenia. 
 
Multiple episodes / established schizophrenia
Several guidelines suggest 2–5 years or longer of maintenance after resolution of an acute episode, particularly once there have been multiple relapses. 
 
Some practice guidelines explicitly advise ≥5 years of continuous treatment after the last episode in patients with several exacerbations, and potentially lifelong treatment in those with aggression, suicidality, or high relapse risk.
 
Relapse risk and long‑term continuation
Stopping antipsychotics within 1–2 years after remission is associated with markedly higher relapse rates (up to ~75% within 12–18 months) compared with continued treatment.
 
References
Barlati, S., Nibbio, G. & Vita, A. (2024, Febriuary 15). 37(3):131-139. Evidence-Based Psychosocial Interventions in Schizophrenia: A Critical Review. Current Opinion in Psychiatry.
 
Bighelli, I., Rodolico, A., Garcia-Mieres, H., Pitschel-Walz, G., Hansen, W-P., et al. (2021, November). 8(11):969-980. Psychosocial and Psychological Interventions for Relapse Prevention in Schizophrenia: A Systematic Review and Network Meta-Analysis. The Lancet Psychiatry.
 
Ceraso, A., Lin, J.J., Schneider-Thoma, J., Siafis, S., Tardy, M. et al. (2020, August 11). 2020(8). Maintenance Treatment with Antipsychotic Drugs for Schizophrenia.Cochrane Database Systematic Reviews.
 
Correll, C.U., Rubio, J.M. & Kane, J.M. (2018, June). 17(2):149-160. What is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People with Schizophrenia? World Psychiatry.
 
Emsley, R., Kilian, S. & Phahladira, L. (2016, May). 29(3):224-229. How Long Should Antipsychotic Treatment be Continued After a Single Episode of Schizophrenia? Current Opinion in Psychiatry.
 
Gaebel, W., Stricker, J. & Riesbeck, M. (2020, November). 225; 4-14. The Long-Term Antipsychotic Treatment of Schizophrenia: A Selective Review of Clinical Guidelines and Clinical Case Examples. Schizophrenia Research.
 
Lawrence, R.E. (2022, October 18). 3(1). Antipsychotic Maintenance Treatment for Patients with Schizophrenia: The Need for Placebo-Controlled Trials and the Risk of Paradigm Shifts. Schizophrenia Bulletin Open
 
McCutheon, R.A., Pillinger, T., Varvari, I., Halstead, S., Ayinde, O.O., et al. (2025, May). 12(5):384-394. Integrate: International Guidelines for the Algorithmic Treatment of Schizophrenia. The Lancet Psychiatry.
 
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T. & Teehan, M. (2017, July 13). 62(9):604-616. Guidelines for the Pharmacotherapy of Schizophrenia in Adults. Canadian Journal of Psychiatry.
 
Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., et al. (2018, June 29). Maintenance Antipsychotic Treatment Versus Discontinuation Strategies Following Remission from First Episode Psychosis: Systematic Review.British Journal in Psychiatry Open. 
 
Young, A.S., Niv, N., Chinman, M., Dixon, L., Eisen, S.V., et al. (2010, July 25). 47(2):123-135. Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI. Community Mental Health.